Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

Management believes that using Adjusted EBITDA as a metric can enhance an overall understanding of the Company's expected financial performance from ongoing operations, and Adjusted EBITDA is used by management for that purpose. We believe that Adjusted EBITDA is frequently used by analysts, investors and other interested parties in evaluating companies such as ours and that it provides a useful measure of our financial performance since its use eliminates the effects of period to period changes in costs associated with impairment of assets related to capital investments, interest on our debt, capital lease obligations and non-cash stock based compensation charges. In addition, under our credit facilities with Gemino Healthcare Finance LLC, we are required to maintain minimum levels of Adjusted EBITDA.

There are limitations inherent in non-GAAP financial measures such as Adjusted EBITDA in that they exclude a variety of charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of the Company's recorded costs against its revenue. Management compensates for these limitations in non-GAAP measures by also evaluating our performance based on traditional GAAP financial measures. Accordingly, in analyzing our future financial performance, investors should consider these non-GAAP results together with GAAP results, rather than as an alternative to GAAP basis financial measures.

    Contact:
    Matt Clawson
    949.474.4300
    matt@allencaron.com

TABLES FOLLOW


                                Clarient, Inc.
               Condensed Consolidated Statements of Operations
              (in thousands, except share and per share amounts)
                                 (Unaudited)

                                   Three Months Ended      Nine Months Ended
           
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... on Friday, August 22 at 2:00 pm ET.  ... CEO, will provide a brief review of SQI,s recent ... , a diagnostics industry veteran recently appointed to the ...
(Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... Provides HIV-Resistant Immune CellsRICHMOND, Calif., Feb. 3 Sangamo ... that its collaborators at the University of Pennsylvania ... evaluate SB-728-T for the treatment of HIV/AIDS. Based on ... has been shown in an animal model of ...
... face of a recession is no small feat for any company. ... Sudberg called "being in the right place at the right time" and ... ... CA (PRWEB) February 2, 2009 -- Sidney Sudberg, Founder, CEO and Chief ...
... 2 Since the cloning of Dolly the ... has been considered a promising way to generate human, patient-specific ... eggs has led to efforts to substitute animal oocytes. However, ... Volume 11, Number 2, 2009 issue of Cloning and ...
Cached Biology Technology:Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 2Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 3Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 4Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 5Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 6Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 7Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 2Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 3Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... SPRING HARBOR, N.Y. (Nov. 12, 2008) For ... for written exams on theoretical concepts, it can be ... skills used in the clinic. The third edition ... for these daunting practical-skills tests, Clinical Skills for ...
... is proud to acknowledge the work of 12 outstanding ... new ideas, recognize leadership in gerontological teaching and service, ... award presentations will take place at GSA,s 61st Annual ... 2008, in National Harbor, MD , at the ...
... November 09, 2008─Bronx, NY─ In a breakthrough study appearing ... researchers at Albert Einstein College of Medicine of Yeshiva ... viewing individual breast cancer cells for several days at ... Lipper Biophotonics Center, provides detail on how cancer cells ...
Cached Biology News:New book helps medical students master clinical skills 2GSA congratulates 2008 award winners 2GSA congratulates 2008 award winners 3Einstein researchers develop a new way to study how breast cancer spreads 2Einstein researchers develop a new way to study how breast cancer spreads 3
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
Biology Products: